Effects of oral contraceptives on hemostasis and thrombosis

American Journal of Obstetrics and Gynecology

Volumn 180, Issue 7 II, 1999, Pages

  Rosing, J ^a   Tans, G ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Activated protein C resistance; Factor V Leiden; Oral contraceptives; Second generation progestogens; Third generation progestogens; Venous thromboembolism

Indexed keywords

ACTIVATED PROTEIN C; BLOOD CLOTTING FACTOR 5 LEIDEN; GESTAGEN; ORAL CONTRACEPTIVE AGENT; THROMBIN;

ACTIVATED PROTEIN C RESISTANCE; GENE MUTATION; HEMOSTASIS; HETEROZYGOTE; HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; VEIN THROMBOSIS;

EID: 0032976313     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0002-9378(99)70699-x     Document Type: Review

References (28)

1. WM Jordan Pulmonary embolism Lancet 2 1961 1146 1147
2. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception Lancet 346 1995 1575 1582
3. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception Lancet 346 1995 1582 1588
4. H Jick SS Jick V Gurewich M Wald Myers C. Vasilakis Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components Lancet 346 1995 1589 1593
5. JR Newton Classification and comparison of oral contraceptives containing new generation progestagens Hum Reprod Update 1 1995 231 263
6. C Kluft M. Lansink Effects of oral contraceptives on haemostasis variables Thromb Haemost 78 1997 315 326
7. O Olivieri S Friso F Manzato A Guella F Bernardi B Lunghi Resistance to activated protein C in healthy women taking oral contraceptives Brit J Haematol 91 1995 465 470
8. CM Henkens VJ Bom AJ Seinen J. van der Meer Sensitivity to activated protein C: influence of oral contraceptives and sex Thromb Haemost 73 1995 402 404
9. J Rosing G Tans GAF Nicolaes MCLGD Thomassen Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second- and third-generation oral contraceptives Br J Haematol 97 1997 233 238
10. JH Griffin B Evatt TS Zimmerman AJ Kleiss C. Wideman Deficiency of protein C in congenital thrombotic disease J Clin Invest 68 1981 1370 1373
11. HP Schwarz M Fischer P Hopmeier MA Batard JH Griffin Plasma protein S deficiency in familial thrombotic disease Blood 64 1984 1297 1300
12. B Dahlbäck M Carlsson PJ Svensson Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C Proc Natl Acad Sci U S A 90 1993 1004 1008
13. T Koster FR Rosendaal H de Ronde E Briet JP Vandenbroucke RM Bertina Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study Lancet 342 1993 1503 1506
14. FR Rosendaal T Koster JP Vandenbroucke PH Reitsma High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance) Blood 85 1995 1504 1508
15. PJ Svensson B. Dahlbäck Resistance to activated protein C as a basis for venous thrombosis N Engl J Med 330 1994 517 522
16. RM Bertina BP Koeleman T Koster FR Rosendaal RJ Dirven H De Ronde Mutation in blood coagulation factor V associated with resistance to activated protein C Nature 369 1994 64 67
17. J Voorberg J Roelse R Koopman H Büller F Berends JW Ten Cate Association of idiopathic venous thromboembolism with single point-mutation at Arg506 of factor V Lancet 343 1994 1535 1536
18. JS Greengard X Sun X Xu JA Fernandez JH Griffin B. Evatt Activated protein C resistance caused by Arg506Gln mutation in factor Va Lancet 343 1994 1361 1362
19. B Zöller B. Dahlbäck Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis Lancet 343 1994 1536 1538
20. HC Hemker GM Willems S. Beguin A computer assisted method to obtain the prothrombin activation velocity in whole plasma independent of the thrombin decay processes Thromb Haemost 56 1986 9 17
21. HC Hemker S. Beguin Thrombin generation in plasma: its assessment via the endogenous thrombin potential Thromb Haemost 74 1995 134 138
22. GAF Nicolaes MCLGD Thomassen G Tans J Rosing HC Hemker Effect of activated protein C on thrombin generation and on the thrombin potential in plasma of normal and APC-resistant individuals Blood Coagul Fibrinolysis 8 1997 28 38
23. B Zöller PJ Svensson X. He B. Dahlbäck Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C J Clin Invest 94 1994 2521 2524
24. JP Vandenbroucke T Koster E Briet PH Reitsma RM Bertina FR Rosendaal Increased risk of venous thrombosis in oral conceptive users who are carriers of factor V Leiden mutation Lancet 344 1994 1453 1457
25. KW Bloemenkamp FR Rosendaal FM Helmerhorst HR Buller JP Vandenbroucke Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestogen Lancet 346 1995 1593 1596
26. Ø Lidegaard I Milsom MA Lewis Oral contraceptives and venous thromboembolism Lancet 349 1997 1621 1623
27. W Schramm LA Heineman Oral contraceptives and venous thromboembolism: acquired APC resistance? Br J Haematol 98 1997 491 493
28. Curvers J, Thomassen MCLDG, Nicolaes GAF, van Oerle R, Hamulyak K, Hemker HC, et al. Acquired APC resistance and oral contraceptives: differences between two functional tests. Br J Haematol;105:88-94.